Request for Nominations for Voting Members on a Public Advisory Committee; Tobacco Products Scientific Advisory Committee, 64505-64506 [2013-25541]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 209 / Tuesday, October 29, 2013 / Notices
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2013–25428 Filed 10–28–13; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
National Center for Injury Prevention
and Control, (BSC, NCIPC)
mstockstill on DSK4VPTVN1PROD with NOTICES
In accordance with Section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces, the following meeting of the
aforementioned committee:
Time and Date: 8:30 a.m.–4:30 p.m.
Eastern Time, November 15, 2013.
Place: Teleconference.
Status: The meeting is open to the public;
the toll free dial in number is 1–877–937–
9818 and the passcode is 7551384.
Purpose: The board makes
recommendations regarding policies,
strategies, objectives, and priorities, and
reviews progress toward injury prevention
goals and provides evidence in injury
prevention-related research and programs.
The board provides advice on the appropriate
balance of intramural and extramural
research, and provides advice on the
structure, progress and performance of
intramural programs. The Board of Scientific
Counselors is also designed to provide
guidance on extramural scientific program
matters, including the: (1) Review of
extramural research concepts for funding
opportunity announcements; (2) conduct of
Secondary Peer Review of extramural
research grants, cooperative agreements, and
contracts applications received in response to
the funding opportunity announcements as it
relates to the Center’s programmatic balance
and mission; (3) submission of secondary
review recommendations to the Center
Director of applications to be considered for
funding support; (4) review of research
portfolios, and (5) review of program
proposals. The board shall provide guidance
on the National Center of Injury Prevention
and Control’s programs and research
activities by conducting scientific peer
review of intramural research and programs
within the National Center for Injury
Prevention and Control; by ensuring
adherence to Office of Management and
Budget requirements for intramural peer
review; and by monitoring the overall
direction, focus, and success of the National
Center for Injury Prevention and Control.
Matters to be Discussed: The BSC, NCIPC
will discuss the recommendations provided
by the expert panel on the Health
VerDate Mar<15>2010
18:15 Oct 28, 2013
Jkt 232001
Communication Portfolio Review that has
been conducted and to discuss research
strategies needed to guide the Center’s focus.
The BSC members will also discuss potential
topics for the upcoming Portfolio Review.
There will be 15 minutes allotted for public
comments at the end of the open session.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Gwendolyn H. Cattledge, Ph.D., M.S.E.H.,
Designated Federal Official, NCIPC, CDC,
4770 Buford Highway NE., Mailstop F–63,
Atlanta, Georgia 30341, Telephone: (770)
488–1430.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. 2013–25427 Filed 10–28–13; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Request for Nominations for Voting
Members on a Public Advisory
Committee; Tobacco Products
Scientific Advisory Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is requesting
nominations for voting members to
serve on the Tobacco Products Scientific
Advisory Committee, Office of Science,
Center for Tobacco Products.
FDA seeks to include the views of
women and men, members of all racial
and ethnic groups, and individuals with
and without disabilities on its advisory
committees and, therefore, encourages
nominations of appropriately qualified
candidates from these groups.
DATES: Nominations received on or
before December 30, 2013, will be given
first consideration for membership on
the Tobacco Products Scientific
Advisory Committee. Nominations
received after December 30, 2013, will
be considered for nomination to the
committee as later vacancies occur.
ADDRESSES: All nominations for
membership should be sent
electronically to cv@oc.fda.gov or by
SUMMARY:
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
64505
mail to Advisory Committee Oversight
and Management Staff, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5103, Silver Spring,
MD 20993–0002.
FOR FURTHER INFORMATION CONTACT:
Regarding all nomination questions for
membership, the primary contact is:
Caryn Cohen, Office of Science, Center
for Tobacco Products, Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 1–877–287–1373
(choose Option 5), FAX: 240–276–3655,
email: TPSAC@fda.hhs.gov.
Information about becoming a
member on an FDA advisory committee
can also be obtained by visiting FDA’s
Web site by using the following link:
https://www.fda.gov/Advisory
Committees/default.htm.
SUPPLEMENTARY INFORMATION: FDA is
requesting nominations for voting
members on the Tobacco Products
Scientific Advisory Committee.
Elsewhere in this issue of the Federal
Register, FDA is publishing a separate
document announcing the Request for
Nominations for Nonvoting Industry
Representatives on the Tobacco
Products Scientific Advisory
Committee.
I. General Description of the Committee
Duties
The Tobacco Products Scientific
Advisory Committee advises the
Commissioner or designee in
discharging responsibilities as they
relate to the regulation of tobacco
products. The Committee reviews and
evaluates safety, dependence, and
health issues relating to tobacco
products and provides appropriate
advice, information, and
recommendations to the Commissioner
of Food and Drugs.
II. Criteria for Voting Members
The Committee shall consist of 12
members including the Chair. Members
and the Chair are selected by the
Commissioner or designee from among
individuals knowledgeable in the fields
of medicine, medical ethics, science, or
technology involving the manufacture,
evaluation, or use of tobacco products.
Members will be invited to serve for
overlapping terms of up to 4 years.
Almost all non-Federal members of this
committee serve as Special Government
Employees. The Committee shall
include nine technically qualified
voting members, selected by the
Commissioner or designee. The nine
voting members shall be physicians,
dentists, scientists, or health care
professionals practicing in the area of
oncology, pulmonology, cardiology,
E:\FR\FM\29OCN1.SGM
29OCN1
64506
Federal Register / Vol. 78, No. 209 / Tuesday, October 29, 2013 / Notices
toxicology, pharmacology, addiction, or
any other relevant specialty.
In addition to the voting members, the
committee shall include three nonvoting
members who are identified with
industry interests. These members shall
include one representative of the
tobacco manufacturing industry, one
representative of the interests of tobacco
growers, and one representative of the
interests of the small business tobacco
manufacturing industry.
III. Nomination Procedures
Any interested person may nominate
one or more qualified individuals for
membership on the advisory committee.
Self-nominations are also accepted.
Nominations must include a current,
´
´
complete resume or curriculum vitae for
each nominee, including current
business address and/or home address,
telephone number, and email address if
available. Nominations must also
specify the advisory committee for
which the nominee is recommended.
Nominations must also acknowledge
that the nominee is aware of the
nomination unless self-nominated. FDA
will ask potential candidates to provide
detailed information concerning such
matters related to financial holdings,
employment, and research grants and/or
contracts to permit evaluation of
possible sources of conflicts of interest.
This notice is issued under the
Federal Advisory Committee Act
(5 U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: October 21, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
meeting will start on November 21, 2013
at 8:00 a.m. and will end on November
22, 2013 at 1:00 p.m. The meeting is
closed to the public.
Dated: October 23, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: October 24, 2013.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–25468 Filed 10–28–13; 8:45 am]
[FR Doc. 2013–25553 Filed 10–28–13; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Biomedical
Imaging and Bioengineering; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel, October 11,
2013, 10:00 a.m. to 5:00 p.m., National
Institutes of Health, Two Democracy
Plaza, Suite 959, 6707 Democracy
Boulevard, Bethesda, MD 20892, which
was published in the Federal Register
on July 26, 2013, 78 FR 45254.
The meeting notice is amended to
change the date from October 22, 2013,
to November 19–20, 2013 at 8:00 a.m. to
6:00 p.m. The location remains the
same. The meeting is closed to the
public.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2013–25494 Filed 10–28–13; 8:45 am]
[FR Doc. 2013–25470 Filed 10–28–13; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
National Institutes of Health
Center for Scientific Review; Amended
Notice of Meeting
mstockstill on DSK4VPTVN1PROD with NOTICES
Dated: October 23, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
Dated: October 23, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Notice is hereby given of a change in
the meeting of the Transplantation,
Tolerance, and Tumor Immunology
Study Section, October 3, 2013, 8:30
a.m. to October 4, 2013, 12:00 p.m.,
Renaissance Washington DC, Dupont
Circle, 1143 New Hampshire Avenue
NW., Washington, DC 20037 which was
published in the Federal Register on
September 9, 2013, 78 FR 174 pgs.
55086–55087.
The meeting will be held at the
Washington Plaza Hotel, 10 Thomas
Circle NW., Washington, DC 20005. The
Jkt 232001
Notice is hereby given of a change in
the meeting of the Tumor Cell Biology
Study Section, October 16, 2013, 08:00
a.m. to October 17, 2013, 05:00 p.m.,
Hotel Kabuki, 1625 Post Street, San
Francisco, CA 94115 which was
published in the Federal Register on
September 17, 2013, 78 FR 57169.
The meeting will be held at the
National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
The meeting will start on November 16,
2013 at 8:00 a.m. and end on November
17, 2013 at 7:00 p.m. The meeting is
closed to the public.
BILLING CODE 4140–01–P
National Institutes of Health
BILLING CODE 4160–01–P
18:15 Oct 28, 2013
Center for Scientific Review; Amended
Notice of Meeting
National Institutes of Health
[FR Doc. 2013–25541 Filed 10–28–13; 8:45 am]
VerDate Mar<15>2010
BILLING CODE 4140–01–P
National Institute of Biomedical
Imaging and Bioengineering; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel, October 22,
2013, 11:00 a.m. to 5:00 p.m., National
Institutes of Health, Two Democracy
Plaza, Suite 951, 6707 Democracy
Boulevard, Bethesda, MD 20892, which
was published in the Federal Register
on September 10, 2013, 78 FR 55268.
The meeting notice is amended to
change the date from October 22, 2013,
to December 11, 2013. The time and
location remains the same. The meeting
is closed to the public.
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Center for Scientific Review; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel,
October 11, 2013, 08:00 a.m. to October
11, 2013, 05:00 p.m., Doubletree Hotel
Washington, 1515 Rhode Island Ave.
NW., Washington, DC 20005 which was
published in the Federal Register on
September 11, 2013, 78 FR Pgs. 55752–
55753.
The meeting will be held at National
Institutes of Health, 6701 Rockledge Dr.,
Bethesda, MD 20892. The meeting will
start on November 15, 2013 at 9:00 a.m.
and end on November 15, 2013 at 4:00
p.m. The meeting is closed to the
public.
E:\FR\FM\29OCN1.SGM
29OCN1
]]>Agencies
[Federal Register Volume 78, Number 209 (Tuesday, October 29, 2013)]
[Notices]
[Pages 64505-64506]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-25541]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-0001]
Request for Nominations for Voting Members on a Public Advisory
Committee; Tobacco Products Scientific Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting
nominations for voting members to serve on the Tobacco Products
Scientific Advisory Committee, Office of Science, Center for Tobacco
Products.
FDA seeks to include the views of women and men, members of all
racial and ethnic groups, and individuals with and without disabilities
on its advisory committees and, therefore, encourages nominations of
appropriately qualified candidates from these groups.
DATES: Nominations received on or before December 30, 2013, will be
given first consideration for membership on the Tobacco Products
Scientific Advisory Committee. Nominations received after December 30,
2013, will be considered for nomination to the committee as later
vacancies occur.
ADDRESSES: All nominations for membership should be sent electronically
to cv@oc.fda.gov or by mail to Advisory Committee Oversight and
Management Staff, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5103, Silver Spring, MD 20993-0002.
FOR FURTHER INFORMATION CONTACT: Regarding all nomination questions for
membership, the primary contact is: Caryn Cohen, Office of Science,
Center for Tobacco Products, Food and Drug Administration, 9200
Corporate Blvd., Rockville, MD 20850, 1-877-287-1373 (choose Option 5),
FAX: 240-276-3655, email: TPSAC@fda.hhs.gov.
Information about becoming a member on an FDA advisory committee
can also be obtained by visiting FDA's Web site by using the following
link: https://www.fda.gov/AdvisoryCommittees/default.htm.
SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting
members on the Tobacco Products Scientific Advisory Committee.
Elsewhere in this issue of the Federal Register, FDA is publishing a
separate document announcing the Request for Nominations for Nonvoting
Industry Representatives on the Tobacco Products Scientific Advisory
Committee.
I. General Description of the Committee Duties
The Tobacco Products Scientific Advisory Committee advises the
Commissioner or designee in discharging responsibilities as they relate
to the regulation of tobacco products. The Committee reviews and
evaluates safety, dependence, and health issues relating to tobacco
products and provides appropriate advice, information, and
recommendations to the Commissioner of Food and Drugs.
II. Criteria for Voting Members
The Committee shall consist of 12 members including the Chair.
Members and the Chair are selected by the Commissioner or designee from
among individuals knowledgeable in the fields of medicine, medical
ethics, science, or technology involving the manufacture, evaluation,
or use of tobacco products. Members will be invited to serve for
overlapping terms of up to 4 years. Almost all non-Federal members of
this committee serve as Special Government Employees. The Committee
shall include nine technically qualified voting members, selected by
the Commissioner or designee. The nine voting members shall be
physicians, dentists, scientists, or health care professionals
practicing in the area of oncology, pulmonology, cardiology,
[[Page 64506]]
toxicology, pharmacology, addiction, or any other relevant specialty.
In addition to the voting members, the committee shall include
three nonvoting members who are identified with industry interests.
These members shall include one representative of the tobacco
manufacturing industry, one representative of the interests of tobacco
growers, and one representative of the interests of the small business
tobacco manufacturing industry.
III. Nomination Procedures
Any interested person may nominate one or more qualified
individuals for membership on the advisory committee. Self-nominations
are also accepted. Nominations must include a current, complete
r[eacute]sum[eacute] or curriculum vitae for each nominee, including
current business address and/or home address, telephone number, and
email address if available. Nominations must also specify the advisory
committee for which the nominee is recommended. Nominations must also
acknowledge that the nominee is aware of the nomination unless self-
nominated. FDA will ask potential candidates to provide detailed
information concerning such matters related to financial holdings,
employment, and research grants and/or contracts to permit evaluation
of possible sources of conflicts of interest.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: October 21, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2013-25541 Filed 10-28-13; 8:45 am]
BILLING CODE 4160-01-P
